<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303536</url>
  </required_header>
  <id_info>
    <org_study_id>OND2</org_study_id>
    <nct_id>NCT01303536</nct_id>
  </id_info>
  <brief_title>Ondansetron Augmentation in Treatment-resistant OCD</brief_title>
  <official_title>Ondansetron Augmentation in Treatment-resistant OCD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Neuroscience, Florence, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Neuroscience, Florence, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether ondansetron augmentation to SSRI will improve
      and ondansetron discontinuation will result in worsening of obsessive compulsive symptoms
      among obsessive compulsive disorder resistant patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>week 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>week 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>week 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Drug Effect scale</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>obsessive compulsive disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly</description>
    <arm_group_label>obsessive compulsive disorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a diagnosis of OCD established by clinical interview with a licensed psychiatrist;

          -  a score of ≥ 24 at the Yale Brown Obsessive Compulsive Scale

          -  a Clinical Global Inventory score ≥ 4, after over 12 weeks of treatment with an
             adequate trial of an selective serotonin reuptake inhibitor at a moderate to high dose

        Exclusion Criteria:

          -  diagnoses of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar
             disorder, current substance dependence or abuse, and current major depressive episode
             preceding the onset of obsessive compulsive disorder

          -  undergoing concomitant behavior therapy

          -  or having significant cardiovascular, hepatic, renal or pulmonary diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Pallanti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Neuroscience</name>
      <address>
        <city>Florence</city>
        <zip>50137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>February 23, 2011</last_update_submitted>
  <last_update_submitted_qc>February 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Stefano Pallanti</name_title>
    <organization>University of Florence</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

